Shares of biopharmaceutical company Affimed (NASDAQ:AFMD) are on the rise today after the U.S. Food and Drug Administration (FDA) gave a go-ahead to its investigational new drug (IND) application for the AFM13 and AB-101 combination’s Phase 2 trial in subjects with relapsed/refractory (r/r) classical Hodgkin Lymphoma (cHL) and CD30-positive peripheral T Cell Lymphoma (PTCL).
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The company plans to begin the trial in the third quarter of this year with data from the safety run-in leg anticipated in H1 2024.
Additionally, the company also announced first quarter numbers with revenue dropping 4.7% year-over-year to €4.51 million. The company’s top line was primarily made up of contributions from Genentech and Roivant collaborations during this period.
Further, a rise in operating expenses meant the company’s net loss per share for the quarter widened to €0.21 from €0.14 a year ago.
Despite today’s price gains, Affimed shares are still down nearly 67.3% over the past year.
Read full Disclosure
